PTK2 and hematopoietic and lymphoid system neoplasm: Despite this, FAK remains little investigated in blood tumors (18), especially from a clinical point of view, with only a few ongoing trials in which FAK inhibitors (e.g., defactinib) are being tested (Table 1).